- Previous Close
0.0040 - Open
0.0040 - Bid 0.0040 x --
- Ask 0.0050 x --
- Day's Range
0.0040 - 0.0040 - 52 Week Range
0.0040 - 0.0150 - Volume
303,374 - Avg. Volume
4,703,617 - Market Cap (intraday)
18.426M - Beta (5Y Monthly) 1.09
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Feb 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe. Its lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
www.oncosil.comRecent News: OSL.AX
View MorePerformance Overview: OSL.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OSL.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OSL.AX
View MoreValuation Measures
Market Cap
18.43M
Enterprise Value
10.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.24
Price/Book (mrq)
2.15
Enterprise Value/Revenue
11.30
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-87.77%
Return on Equity (ttm)
-199.38%
Revenue (ttm)
1.91M
Net Income Avi to Common (ttm)
-12.6M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
8.47M
Total Debt/Equity (mrq)
0.83%
Levered Free Cash Flow (ttm)
-7.9M